Compare · DVAX vs MRK
DVAX vs MRK
Side-by-side comparison of Dynavax Technologies Corporation (DVAX) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DVAX and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $280.47B, about 185.6x DVAX ($1.51B).
- Over the past year, DVAX is up 59.7% and MRK is up 43.6% - DVAX leads by 16.1 points.
- MRK has hit the wire 28 times in the past 4 weeks while DVAX has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 8 for DVAX).
- Company
- Dynavax Technologies Corporation
- Merck & Company Inc.
- Price
- $15.49+0.00%
- $113.55+0.35%
- Market cap
- $1.51B
- $280.47B
- 1M return
- +0.55%
- -4.86%
- 1Y return
- +59.74%
- +43.62%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 0
- 28
- Recent ratings
- 8
- 25
Dynavax Technologies Corporation
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest DVAX
- SEC Form 15-12G filed by Dynavax Technologies Corporation
- SEC Form EFFECT filed by Dynavax Technologies Corporation
- SEC Form 4 filed by Large owner Deep Track Biotechnology Master Fund, Ltd.
- SEC Form S-8 POS filed by Dynavax Technologies Corporation
- SEC Form S-8 POS filed by Dynavax Technologies Corporation
- SEC Form S-8 POS filed by Dynavax Technologies Corporation
- SEC Form S-8 POS filed by Dynavax Technologies Corporation
- SEC Form S-8 POS filed by Dynavax Technologies Corporation
- SEC Form S-8 POS filed by Dynavax Technologies Corporation
- SEC Form S-8 POS filed by Dynavax Technologies Corporation
Latest MRK
- Merck Animal Health Selects Salesforce's Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees
- Citigroup resumed coverage on Merck with a new price target
- SVP Fin. - Global Controller Smart Dalton E. Iii exercised 383 shares at a strike of $112.16 and covered exercise/tax liability with 132 shares, increasing direct ownership by 3% to 9,388 units (SEC Form 4)
- EVP & Pres. MMD Maraldo David R. exercised 552 shares at a strike of $112.16 and covered exercise/tax liability with 159 shares, increasing direct ownership by 2% to 18,212 units (SEC Form 4)
- Amendment: New insider Maraldo David R. claimed ownership of 17,819 shares and claimed ownership of 8,359 units of Common Stock - 401 Plan (SEC Form 3)
- Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
- New insider Maraldo David R. claimed ownership of 8,359 units of Common Stock - 401 Plan and claimed ownership of 17,819 shares (SEC Form 3)
- SEC Form 10-Q filed by Merck & Company Inc.
- EVP, Access, Policy & Comms Guindo Chirfi exercised 1,967 shares at a strike of $110.03 and covered exercise/tax liability with 969 shares, increasing direct ownership by 2% to 61,613 units (SEC Form 4)
- Exe V-P & Pres. MMD Chattopadhyay Sanat exercised 2,597 shares at a strike of $110.03 and covered exercise/tax liability with 1,130 shares, increasing direct ownership by 11% to 15,347 units (SEC Form 4)